Trevor James
The RSV (Respiratory Syncytial Virus) vaccine is an mRNA-based vaccine that helps prevent disease caused by the RSV infection. The vaccine works by sending instructions to host cells in the body to make copies of a specific RSV protein. This protein then triggers the immune system to produce neutralizing antibodies that can recognize and attack the virus. RSV is a common respiratory virus that causes mild, cold-like symptoms, but can lead to severe disease and even death in older people and babies. The mRNA-1345 vaccine, developed by Moderna, is currently undergoing clinical trials to evaluate its safety and efficacy in preventing RSV-associated respiratory disease in older adults.
| Characteristics | Values |
|---|---|
| What is RSV? | Respiratory Syncytial Virus (RSV) is a highly contagious condition that causes mild cold symptoms in most people but can lead to hospitalization and death in older people and babies. |
| How is it spread? | RSV is usually spread through direct contact with the virus such as droplets from another person's cough or sneeze contacting your eyes, nose or mouth. It can also be spread by touching a surface that has a virus on it and then touching your face before washing your hands. |
| Who is at risk? | Older adults and those with comorbidities are at increased risk of severe RSV. |
| What is the vaccine? | There are three RSV vaccines licensed by the Food and Drug Administration (FDA) for use in adults: Abrysvo from Pfizer, Arexvy from GSK, and mResvia from Moderna. |
| How does the vaccine work? | The mResvia shot uses an mRNA platform like the COVID vaccines made by Moderna and Pfizer-BioNTech. The relatively new mRNA technology is a way of sending instructions to host cells in the body for making copies of a specific RSV protein. |
| Who is the vaccine for? | The Centers for Disease Control and Prevention (CDC) recommends RSV vaccination for all adults ages 75 and older and for adults ages 50–74 who are at increased risk of severe RSV. |
| Are there any side effects? | A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the RSV vaccine, mRNA. If you see signs of a severe allergic reaction (rash, hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital. |
Explore related products
$32.99 $32.99
$15.99 $14.95
What You'll Learn
- The RSV vaccine, mRNA can prevent the Respiratory Syncytial Virus (RSV) disease
- The Centers for Disease Control and Prevention (CDC) recommends a one-time dose for adults 75+
- The vaccine is supplied as a single-dose vial of 120 μg of lyophilized preF antigen
- The mRNA-1345 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine
- The mResvia shot uses an mRNA platform like the COVID vaccines
The RSV vaccine, mRNA can prevent the Respiratory Syncytial Virus (RSV) disease
The Respiratory Syncytial Virus (RSV) is a highly contagious condition that usually causes mild cold symptoms. However, it can lead to severe disease and even death in older people and babies. RSV is typically spread through direct contact with the virus, such as through droplets from an infected person's cough or sneeze. It can also spread via touch, for example, by touching a contaminated surface and then touching your face.
There are currently three RSV vaccines licensed by the Food and Drug Administration (FDA) for use in adults: Abrysvo® from Pfizer, Arexvy® from GSK, and mResvia®, from Moderna. The CDC recommends RSV vaccination for all adults aged 75 and older and for adults aged 50-74 who are at increased risk of severe RSV. The vaccine is given as a single injection in the upper arm and can be administered at any time, although late summer and early fall are ideal.
The RSV vaccine has been shown to be safe and effective in clinical trials. A phase 1 clinical trial of the mRNA-1345 vaccine, which included healthy adults aged 65 to 79, demonstrated its safety and ability to induce an immune response. This was followed by a phase 2/3 trial that evaluated the efficacy of the vaccine in preventing RSV-associated respiratory disease. The trial showed high vaccine efficacy, ranging from 68.4% to 83.7%, against RSV-associated respiratory disease with at least two or three signs or symptoms.
In addition to the vaccines for older adults, there are also immunizations available for babies, starting with a maternal RSV vaccine given during pregnancy to protect newborns. The Abrysvo vaccine, in particular, has been shown to reduce the risk of hospitalization in newborns during the first three and six months by 68% and 57%, respectively.
Vaccines Without Aluminum: Do They Exist?
You may want to see also
Explore related products
The Centers for Disease Control and Prevention (CDC) recommends a one-time dose for adults 75+
The Centers for Disease Control and Prevention (CDC) recommends a one-time dose of the RSV vaccine for adults aged 75 and over. RSV, or Respiratory Syncytial Virus, is a highly contagious condition that usually causes mild cold symptoms. However, it can lead to severe illness and even death in older adults and babies. The CDC also recommends the vaccine for adults aged 50–74 who are at increased risk of severe RSV.
There are currently three RSV vaccines licensed by the Food and Drug Administration (FDA) for use in adults: Abrysvo® from Pfizer, Arexvy® from GSK, and mResvia®, from Moderna. Each is given as a single injection, and all are recommended for adults over the age of 60. The mResvia shot is an mRNA vaccine, similar to the COVID-19 vaccines made by Moderna and Pfizer-BioNTech. This relatively new technology sends instructions to host cells in the body to make copies of a specific RSV protein. This protein then triggers the immune system to produce neutralising antibodies that will recognise and attack the actual virus.
The CDC also recommends two immunisations for babies, starting with a maternal RSV vaccine given to mothers during pregnancy to protect newborns. Clinical trials have shown that this reduces the risk of hospitalisation in the first three months by 68% and in the first six months by 57%. For newborns up to eight months old whose mothers did not receive the vaccine, two monoclonal antibody immunisations are recommended.
The RSV vaccine is generally safe, but it is important to be aware of potential adverse reactions. Severe allergic reactions would usually occur within an hour of receiving the vaccine. Signs of a severe allergic reaction include a rash, hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness. If any of these symptoms occur, seek immediate medical attention.
Met Gala and Vaccination: Was It a Must?
You may want to see also
Explore related products
The vaccine is supplied as a single-dose vial of 120 μg of lyophilized preF antigen
The RSV vaccine is supplied in a specific form and quantity, "as a single-dose vial of 120 μg of lyophilized preF antigen". This detailed description provides important information for healthcare professionals and those involved in vaccine distribution and administration.
Firstly, the vaccine is provided in a single-dose vial, meaning it is individually packaged and intended for administration to a single individual. This packaging ensures the correct dosage is delivered and reduces the risk of contamination associated with multi-dose vials.
The quantity of the vaccine is specified as 120 micrograms (μg). This precise measurement indicates the amount of the active ingredient, in this case, the preF antigen, present in each vial. This dosage has been carefully determined through clinical trials and research to ensure both safety and efficacy.
Lyophilization, or freeze-drying, is the process used to prepare the vaccine for long-term storage and transportation. This technique involves freezing the vaccine and then removing the water through a sublimation process, leaving a dry, stable product. Lyophilized vaccines are advantageous as they have an extended shelf life, simplified transportation requirements, and can be stored without stringent temperature control, making global distribution more feasible.
The critical component of the vaccine is the prefusion F antigen, referred to as preF. This antigen is a protein specifically targeting the respiratory syncytial virus (RSV). By including this antigen, the vaccine stimulates the body's immune system to recognize and generate antibodies against the virus, thereby providing protective immunity and reducing the impact of RSV infections.
Overall, the detailed description of the vaccine's supply format is essential for ensuring proper handling, storage, and administration. This, in turn, contributes to the overall effectiveness of the vaccine in preventing and mitigating RSV infections.
American Airlines: Vaccination Rules for Employees
You may want to see also
Explore related products
The mRNA-1345 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine
The RSV (Respiratory Syncytial Virus) vaccine is an mRNA vaccine. It helps protect against the virus that causes RSV disease. The mRNA-1345 vaccine is an RSV vaccine that has been through a Phase 1 clinical trial in healthy older adults aged 65 to 79 years. This trial evaluated the safety, reactogenicity, and immunogenicity of a single injection of the vaccine at 5 dose levels, as well as a booster injection given approximately 12 months after the first injection. The study found that most adverse reactions were mild to moderate with a median duration of 2 days. Injection-site pain, fatigue, headache, and myalgia were the most common adverse reactions.
Lipid nanoparticles are tiny particles made up of lipids, which are types of fats or fat-like substances. They are used as a delivery system for mRNA because they can protect the mRNA from degradation and help it enter the body's cells more efficiently. When the vaccine is administered, the lipid nanoparticles fuse with the cell membrane or are taken up by the cells through endocytosis. This allows the mRNA to be released into the cell cytoplasm, where it can then enter the cell's protein-making machinery and instruct the cell to produce the desired protein.
The use of lipid nanoparticles in the mRNA-1345 vaccine provides several advantages. They help protect the mRNA from degradation by enzymes in the body, increasing the stability of the vaccine. Additionally, lipid nanoparticles can enhance the uptake of mRNA by the body's cells, improving the efficiency of protein production and, consequently, the immune response to the vaccine. Furthermore, lipid nanoparticles are generally considered safe and biocompatible, reducing the potential for adverse reactions to the vaccine.
Massachusetts Vaccination Requirements: What You Need to Know
You may want to see also
Explore related products
The mResvia shot uses an mRNA platform like the COVID vaccines
The mResvia shot is one of the three RSV vaccines licensed by the Food and Drug Administration (FDA) for use in adults. The other two are Arexvy and Abrysvo. The mResvia vaccine uses an mRNA platform similar to the COVID vaccines made by Moderna and Pfizer-BioNTech. The relatively new mRNA technology sends instructions to host cells in the body to make copies of a specific RSV protein. This protein then triggers the immune system to produce neutralizing antibodies that can recognize and attack the actual virus.
The mResvia vaccine is supplied as a single 0.5 mL-dose vial containing 50 μg of nucleoside-modified mRNA encoding the RSV F glycoprotein. It is based on the RSV-A subtype and stabilized in the prefusion conformation (pre-F protein). The vaccine is given as a single injection in the upper arm, much like the flu shot. It is recommended for adults aged 75 and older and for adults aged 50-74 who are at an increased risk of severe RSV.
The RSV vaccine, mRNA, can prevent disease caused by infection with Respiratory Syncytial Virus (RSV). RSV is usually spread through direct contact with the virus, such as droplets from another person's cough or sneeze, or by touching a contaminated surface and then touching your face. In high-risk individuals, RSV can cause shortness of breath, low oxygen levels, and worsen chronic heart or lung disease, leading to hospitalization or even death. The mRNA vaccine helps protect against the virus that causes RSV disease.
There are different types of RSV mRNA vaccines, such as mRNA-1345, which is currently under clinical investigation. This vaccine has shown promising results in phase 1 and phase 2/3 trials, with no significant safety concerns and the ability to induce neutralizing antibodies against both RSV A and B subtypes. The mRNA-1345 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine derived from an RSV A strain and stabilized in the preF conformation.
Overall, the mResvia shot is an important tool in protecting adults, especially those at high risk, from severe RSV disease. Its use of mRNA technology, similar to COVID vaccines, allows it to effectively trigger the body's immune response and produce neutralizing antibodies to fight the virus.
DTap's Tetanus Vaccine: Understanding Its Unique Composition
You may want to see also
Frequently asked questions
The RSV vaccine helps prevent disease caused by infection with the Respiratory Syncytial Virus (RSV). RSV is a common respiratory virus that causes inflammation of the respiratory tract, usually leading to mild, cold-like symptoms.
There are three types of RSV vaccines licensed by the Food and Drug Administration (FDA) for use in adults: Arexvy® from GSK, Abrysvo® from Pfizer, and mResvia®, from Moderna. The Arexvy and Abrysvo vaccines use traditional platforms, while the mResvia shot uses an mRNA platform.
The mRNA-based RSV vaccine uses mRNA technology to send instructions to host cells in the body to make copies of a specific RSV protein. This protein then triggers the immune system to produce neutralizing antibodies that will recognize and attack the actual virus.
